Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Dexmedetomidine
The First People's Hospital of Lianyungang
Heart Injuries
1 trial -
Digoxin
The First People's Hospital of Lianyungang
Healthy
1 trial -
Digoxin
Hospital Authority, Hong Kong
Healthy
1 trial -
Dose escalation
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Poor Graft Function
1 trial -
Drugs administration
Hospital Authority, Hong Kong
Rotator Cuff Tears of the Shoulder
1 trial -
EBV immunological agent
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Malignant Tumor
1 trial -
ESAT6-CFP10
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Healthy
1 trial -
ETH-155008
Xiyuan Hospital of China Academy of Chinese Medical Sciences
NHL, Adult
1 trial -
ETH-155008
Xiyuan Hospital of China Academy of Chinese Medical Sciences
NHL
1 trial -
EVM16
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Advanced or Recurrent Solid Tumors
1 trial -
Engineered mitochondrial vaccine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Advanced Solid Tumor Malignancies
1 trial -
Eprolidone
The First People's Hospital of Lianyungang
Chronic Heart Failure Patients
1 trial -
Esketamine injection group (0.25 mg/kg)
The First People's Hospital of Lianyungang
Esketamine
1 trial -
Ex-vivo expanded allogeneic Ξ³Ξ΄ T cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
AML (Acute Myelogenous Leukemia)
1 trial -
Ex-vivo expanded allogeneic Ξ³Ξ΄T cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-Hodgkin's Lymphoma (NHL)
1 trial -
Exenatide Circular RNA-Lipid Nanoparticle InjectionοΌ CR059οΌοΌ
The First People's Hospital of Lianyungang
T2DM
1 trial -
Experimental Vaccine 1
Xiyuan Hospital of China Academy of Chinese Medical Sciences
COVID-19 Pneumonia
1 trial -
Exposure to sporting events
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Coronary Heart Disease
1 trial -
Extraluminal use of Univent bronchial Blocker
Hospital Authority, Hong Kong
Therapeutic Procedural Complication
1 trial -
FMT capsules
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hypertension
1 trial -
FT-003
The First People's Hospital of Lianyungang
Diabetic Macular Edema
1 trial -
FT-003
The First People's Hospital of Lianyungang
Neovascular Age-related Macular Degeneration
1 trial -
Fast Dual CAR-T Injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
B-cell Lymphoma
1 trial -
Ferric Carboxymaltose Injection
The First People's Hospital of Lianyungang
Healthy Adult
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources